Applications of ApliChip™ CYP450

Molecular Diagnosis

Volumn 9, Issue 3, 2005, Pages 119-127

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CARVEDILOL; CHLORPROMAZINE; CHLORPROPAMIDE; CLOMIPRAMINE; CLOZAPINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESIPRAMINE; DEXTROMETHORPHAN; DILTIAZEM; ENCAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; INDORAMIN; MEFLOQUINE; METHOXYPHENAMINE; METOPROLOL; NEUROLEPTIC AGENT; NORTRIPTYLINE; RISPERIDONE; UNINDEXED DRUG;

ANALYTICAL EQUIPMENT; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DNA MICROARRAY; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; MUTATIONAL ANALYSIS; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PROTEIN MICROARRAY; REVIEW; TARDIVE DYSKINESIA; TECHNOLOGY; TOXICOLOGY; GENETIC POLYMORPHISM; GENETICS; MUTATION;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TOXICOLOGY;

EID: 27744491843     PISSN: 10848592     EISSN: 10848592     Source Type: Journal    
DOI: 10.2165/00066982-200509030-00002     Document Type: Review

References (35)

1. Solus JF, Arietta BJ, Harris JR, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5: 895-931
2. Williams PA, Cosme J, Ward A, et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464-8
3. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16
4. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304
5. Gharavi N, El-Kadi AO. Expression of cytochrome P450 in lung tumor. Curr Drug Metab 2004; 5: 203-10
6. Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 2003; 42: 153-78
7. Jetter A, Kinzig-Schippers M, Skott A, et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 2004; 60: 165-71
8. Ledesma MC, Undez JA. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin Chem 2005 Jun; 51 (6): 939-43
9. James HM, Coller JK, Gillis D, et al. A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther 2004; 42: 719-23
10. Soderback E, Zackrisson AL, Lindblom B, et al. Determination of CYP2D6 gene copy number by pyrosequencing. Clin Chem 2005; 51: 522-31
11. Aquilante CL, Lobmeyer MT, Langaee TY, et al. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004; 24: 720-6
12. McConnachie LA, Bodor M, Phillips B, et al. An RT-PCR-based strategy to estimate full-length CYP2D6 mRNA copy number. Genet Test 2004; 8: 313-8
13. Nevilie M, Selzer R, Aizenstein B, et al. Characterization of cytochrome P450 2D6 alleles using the Invader system. Biotechniques 2002; Suppl.: 34-8, 40-3
14. Mills JB, Rose KA, Sadagopan N, et al. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004; 309: 303-9
15. Koch WH. Technology platforms for pharmacogenomic diagnostic assays. Nat Rev Drug Discov 2004; 3: 749-61
16. Jain KK. Biochips for gene spotting. Science 2001; 294: 621-3
17. Koch WH. AmpliChip CYP450. In: Wong SH, Linder MW, Valdes R, editors. Clinical pharmacogenomics. Milwaukee (WI): AACC Press, 2005
18. Roche Diagnostics. AmpliChip CYP450. Product information, 2005 [online]. Available from URL: http://www.roche-diagnostics.com/products_services/ amplichip_cyp450.html [Accessed 2005 Oct 4]
19. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003; 49: 542-51
20. Cintron V, Watters J, Fairchild M, et al. Combination of the AmpliChip. CYP450 Microarray RUO and GenomiPhi. technology to genotype CYP2D6 and CYP2C19 alleles from whole blood, serum and plasma [abstract 55]. American Association for Clinical Chemistry Meeting; 2004 Apr 29; San Jose (CA)
21. Heller T, Kirchheiner J, Victor W, et al. Assessment of Amplichip CYP450-based CYP2D6-genotyping and phenotype prediction compared to PCR-RFLP-ge-notyping and phenotyping by metoprolol pharmacokinetics [abstract]. Ther Drug Monit 2005; 27: 221
22. Roots I, Gerloff T, Meisel C, et al. Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev 2004; 36: 617-38
23. Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376-85
24. Kirchheiner J, Henckel HB, Meineke I, et al. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004; 24: 647-52
25. Nikoloff D, Shim JC, Fairchild M, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2002; 2: 400-7
26. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27
27. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 453-60
28. Lytton SD, Berg U, Nemeth A, et al. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs. Clin Exp Immunol 2002; 127: 293-302
29. Colburn DE, Giles FJ, Oladovich D, et al. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004; 9: 217-21
30. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 2005; 44: 349-66
31. Dambach D, Andrews B, Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 2005 Jun; 33: 17-26
32. Lee MY, Park CB, Dordick JS, et al. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc Natl Acad Sci U S A 2005; 102: 983-7
33. Jain KK. Personalised medicine. Curr Opin Mol Ther 2002; 4: 548-58
34. Jain KK. Personalized medicine. In: Fuchs J, Podda M, editors. Encyclopedia of diagnostic genomics and proteomics. New York: Marcel Dekkar Inc., 2005: 994-9
35. Jain KK. Applications of biochips: from diagnostics to personalized medicine. Curr Opin Drug Discov Devel 2004; 7: 285-9